Table 2.

Comparison of cervical immune cell populations and soluble immune factors in cervicovaginal lavage in 18–24 year old women from Kisumu, Kenya and San Francisco, USA.

Variable	Kisumu		San Francisco
Variable	Median [IQR]	Proportion [IQR]	Median [IQR]	Proportion [IQR]	p-Value^*	p-Value^†
CD4+	187 [31, 403]	-	304 [200, 640]	-	0.05	-
CD4+/CD69+	51.5 [11.5, 91.9]	15.7 [8.3, 56.7]	10 [6, 23]	3.6 [2.3, 6.5]	0.006	<0.00001
CD4+/CCR5+	119 [24, 253]	66.5 [57, 84.2]	205 [95, 321]	60.2 [43, 78]	0.15	0.23
CD4+/CD69+/CCR5+	43 [9, 94]	15.3 [6.7, 45.0]	9 [5, 21]	2.7 [1.9, 6.2]	0.01	<0.002
CD8+	143 [38, 305]	-	230 [142, 526]	-	0.08	-
CD8+/CD69+	36 [8, 86.5]	25.8 [8.7, 59.6]	12 [6, 35]	5.1 [3.5, 9.6]	0.11	<0.0001
CD1a+	134 [90, 330]	-	320 [215, 616.5]	-	0.03	-
CD1a+/DC-SIGN+	90 [69, 123]	66.7 [45.3, 84.6]	197 [79, 361]	65.4 [44.8, 82.4]	0.038	0.90
CD11c+	267 [130, 791]	-	1285 [279, 2705]	-	0.01	-
CD11c+/DC-SIGN+	113 [80, 213]	56.7 [31.5, 71.7]	301 [118, 831]	44.5 [15, 57.4]	0.01	0.31
CD14+	356 [121, 473]	-	662 [249, 1067]	-	0.05	-
CD14+/DC-SIGN+	167 [74, 342]	79.2 [62.3, 86.1]	221 [162, 647]	62.1 [30.1, 82.1]	0.20	0.85
Concentration pg/mL
SLPI	190 [96, 519]	-	474 [206, 817]	-	0.009
GM-CSF	0.06 [0.06, 0.3]	-	0.6 [0.06, 1.3]	-	0.004
IFN-γ	0.15 [0.06, 0.7]	-	0.5 [0.2, 0.8]	-	0.15
IL-2	0.2 [0.06, 0.7]	-	0.06 [0.06, 0.2]	-	0.02
IL-4	0.3 [0.06, 0.8]	-	1.7 [0.06, 6.8]	-	0.06
IL-6	10.8 [3.3, 33.9]	-	17.3 [5.7, 27.7]	-	0.5
IL-8	166 [85.5, 444]	-	345 [146, 1,500]	-	0.04
IL-10	0.4 [0.1, 2.1]	-	0.3 [0.06, 307.1]	-	0.59
IL-12	0.1 [0.06, 0.2]	-	0.1 [0.06, 0.2]	-	0.32
IL-13	0.06 [0.06, 0.4]	-	0.08 [0.06, 0.4]	-	0.54
IL-1β	0.2 [0.06, 1.1]	-	1.0 [0.06, 12.0]	-	0.08
TNF	0.1 [0.06, 0.7]	-	0.06 [0.06, 0.4]	-	0.75

p-Value represents comparison of number of cells between sites using the Wilcoxon Rank-Sum Test

^†

p-Value represents comparison of proportion of cells between sites using negative binomial regression